Quince buys a rare disease biotech; Heron reduces headcount
Quince Therapeutics will buy the private biotech EryDel SpA in a stock deal, with up to $485 million on the line …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
